112 related articles for article (PubMed ID: 2623545)
1. [Rheology of giant capillary occlusion in secondary Raynaud's phenomenon within the scope of systemic sclerosis].
Schmid-Schönbein H; Goebel W; Perkkiö J; Polster H; Jacobs M; Lemmens HA
Vasa Suppl; 1989; 27():61-3. PubMed ID: 2623545
[No Abstract] [Full Text] [Related]
2. Endothelin-1 and cold provocation in health, primary Raynaud's phenomenon, and progressive systemic sclerosis.
Dörffler-Melly J; Lüscher TF; Wenk M; Wen S; Bollinger A; Franzeck UK
Microvasc Res; 1996 Sep; 52(2):193-7. PubMed ID: 8901448
[No Abstract] [Full Text] [Related]
3. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
Fries R; Shariat K; von Wilmowsky H; Böhm M
Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885
[TBL] [Abstract][Full Text] [Related]
4. Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis: a comparative study.
Pamuk GE; Turgut B; Pamuk ON; Vural O; Demir M; Cakir N
Blood Coagul Fibrinolysis; 2007 Jun; 18(4):297-302. PubMed ID: 17473568
[TBL] [Abstract][Full Text] [Related]
5. [Hemorrheology and neurovascular syndromes of the extremities].
Sergio G; Artale F; Francisci A; Giunti P; Perego MA
Ric Clin Lab; 1983; 13 Suppl 3():481-5. PubMed ID: 6673031
[TBL] [Abstract][Full Text] [Related]
6. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
[TBL] [Abstract][Full Text] [Related]
7. Differences in red cell behaviour between patients with Raynaud's phenomenon and systemic sclerosis and patients with Raynaud's disease.
Rustin MH; Kovacs IB; Sowemimo-Coker SO; Maddison PJ; Kirby JD
Br J Dermatol; 1985 Sep; 113(3):265-72. PubMed ID: 3877518
[TBL] [Abstract][Full Text] [Related]
8. [Raynaud's phenomena: diagnostic and treatment study].
Priollet P
Rev Prat; 1998 Oct; 48(15):1659-64. PubMed ID: 9814067
[TBL] [Abstract][Full Text] [Related]
9. Raynaud's phenomenon and systemic sclerosis.
Generini S; Kahaleh B; Matucci-Cerinic M; Pignone A; Lombardi A; Ohtsuka T
Ann Ital Med Int; 1996; 11(2):125-31. PubMed ID: 8974438
[TBL] [Abstract][Full Text] [Related]
10. [Blood rheology in Raynaud's disease].
Larcan A; Schmidt C; Stoltz JF; Voisin P
J Mal Vasc; 1984; 9(1):1-6. PubMed ID: 6707529
[TBL] [Abstract][Full Text] [Related]
11. [Decreased blood fluidity in progressive systemic scleroderma].
Ernst E; Lohmaier EF; Meurer M; Gerstmeier J
Z Rheumatol; 1990; 49(3):155-9. PubMed ID: 2378174
[TBL] [Abstract][Full Text] [Related]
12. Digital blood flow and nailfold capillary microscopy in Raynaud's phenomenon.
Lee P; Sarkozi J; Bookman AA; Keystone EC; Armstrong SK
J Rheumatol; 1986 Jun; 13(3):564-9. PubMed ID: 3735278
[TBL] [Abstract][Full Text] [Related]
13. Low plasma protein nitrotyrosine levels distinguish primary Raynaud's phenomenon from scleroderma.
Kingdon EJ; Mani AR; Frost MT; Denton CP; Powis SH; Black CM; Moore KP
Ann Rheum Dis; 2006 Jul; 65(7):952-4. PubMed ID: 16308344
[TBL] [Abstract][Full Text] [Related]
14. Rheological properties of blood in Raynaud's phenomenon.
Wichers G; Smit AJ; van der Meer J; Wouda AA; Halie MR
Vasa Suppl; 1992; 34():29-33. PubMed ID: 1529415
[TBL] [Abstract][Full Text] [Related]
15. Association between capillaroscopy, haemorheological variables and plasma proteins in patients bearing Raynaud's phenomenon.
Spengler MI; Svetaz MJ; Leroux MB; Leiva ML; Bottai HM
Clin Hemorheol Microcirc; 2004; 30(1):17-24. PubMed ID: 14967879
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous neutrophil activation in patients with primary Raynaud's phenomenon and systemic sclerosis.
Stevens TR; Hall ND; McHugh NJ; Maddison PJ
Br J Rheumatol; 1992 Dec; 31(12):856. PubMed ID: 1458295
[No Abstract] [Full Text] [Related]
17. Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma.
Freedman RR; Girgis R; Mayes MD
J Rheumatol; 2001 Jan; 28(1):119-21. PubMed ID: 11196511
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of haemostatic parameters and circadian variations of the haemostatic system in patients with systemic sclerosis and Raynaud's phenomenon.
Trifiletti A; Bartolone S; Scamardi R; Pizzoleo MA; Sottilotta G; Larosa D; Barbera N
Panminerva Med; 2000 Mar; 42(1):7-9. PubMed ID: 11019597
[TBL] [Abstract][Full Text] [Related]
19. [Esophageal motility in Raynaud's disease, systemic scleroderma and presclerodermal Raynaud's syndrome].
Hostein J; Bost R; Carpentier P; Franco A; Fournet J
Gastroenterol Clin Biol; 1985 Feb; 9(2):130-5. PubMed ID: 3979734
[TBL] [Abstract][Full Text] [Related]
20. Increased plasma adrenomedullin concentrations in patients with Raynaud's phenomenon.
Letizia C; Danese C; D'Erasmo E
J Rheumatol; 1999 Mar; 26(3):759-60. PubMed ID: 10090204
[No Abstract] [Full Text] [Related]
[Next] [New Search]
